852 reports of this reaction
1.2% of all APREPITANT reports
#20 most reported adverse reaction
GASTROINTESTINAL DISORDER is the #20 most commonly reported adverse reaction for APREPITANT, manufactured by Merck Sharp & Dohme LLC. There are 852 FDA adverse event reports linking APREPITANT to GASTROINTESTINAL DISORDER. This represents approximately 1.2% of all 73,587 adverse event reports for this drug.
Patients taking APREPITANT who experience gastrointestinal disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROINTESTINAL DISORDER is a less commonly reported adverse event for APREPITANT, but still significant enough to appear in the safety profile.
In addition to gastrointestinal disorder, the following adverse reactions have been reported for APREPITANT:
The following drugs have also been linked to gastrointestinal disorder in FDA adverse event reports:
GASTROINTESTINAL DISORDER has been reported as an adverse event in 852 FDA reports for APREPITANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROINTESTINAL DISORDER accounts for approximately 1.2% of all adverse event reports for APREPITANT, making it a notable side effect.
If you experience gastrointestinal disorder while taking APREPITANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.